Home

Jennifer Evans Stacey

CIK 1321326 · Chief Legal Officer · last filed 2026-08-14

Jennifer Evans Stacey is a Chief Legal Officer who has filed 29 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider was granted $450.0K of NEOG on Aug 14, 2026. Across all open-market trades the lifetime net is −$745.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $455.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$455.0K

Companies

5

Total Filings

29

Lifetime Open-Market Net

-$745.2K

Filer Profile

Reported Address
2001 MARKET STREET
SUITE 3915 UNIT #15
PHILADELPHIA, PA 19103
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NEOG Chief Legal Officer 38,627 $11.78 $455.0K $0 2 2026-08-14
CNTX Director — $0.35 — $0 5 2026-06-26
Galera Therapeutics, Inc. (GRTX) Delisted See Remarks — $17.60 — $0 3 2023-02-28
ANTARES PHARMA, INC. (ATRS) Delisted SVP, General Counsel & Secty 92,042 $5.59 $514.5K $0 2 2015-06-01
AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted Executive VP & General Counsel 16,878 — — -$745.2K 17 2011-04-04

Recent Filings

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-14 NEOG Grant (A) +38,627 $450.0K EDGAR
2026-06-26 CNTX Grant (A) — $0 EDGAR
2026-05-04 NEOG Grant (A) +39,349 $375.0K EDGAR
2025-06-12 CNTX Grant (A) — $0 EDGAR
2024-06-14 CNTX Grant (A) — $0 EDGAR
2023-05-31 CNTX Grant (A) — $0 EDGAR
2023-02-28 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
2022-06-03 CNTX Grant (A) — $0 EDGAR
2022-03-02 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
2021-10-12 Galera Therapeutics, Inc. (GRTX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 29
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.